Sugi Predict

Sugi Predict / Targets / KDM4C

KDM4C

Lysine-specific demethylase 4C · Q9H3R0 · KDM4C on Sugi Atlas →

115,608 patent compounds predicted against KDM4C, 56,982 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL115648 SCHEMBL115648 0.56 19/20
SCHEMBL115797 SCHEMBL115797 0.59 18/20
SCHEMBL116060 SCHEMBL116060 0.55 18/20
SCHEMBL71335 SCHEMBL71335 0.65 16/20
SCHEMBL82604 SCHEMBL82604 0.59 16/20
SCHEMBL188821 SCHEMBL188821 0.55 16/20
SCHEMBL123203 SCHEMBL123203 0.51 15/20
SCHEMBL116912 SCHEMBL116912 0.59 14/20
SCHEMBL115907 SCHEMBL115907 0.53 13/20
SCHEMBL115719 SCHEMBL115719 0.53 12/20
Butyric Acid Butyric Acid (SCHEMBL145707) 0.42 12/20
SCHEMBL131476 SCHEMBL131476 0.40 11/20
SCHEMBL70700 SCHEMBL70700 0.78 10/20
SCHEMBL118817 SCHEMBL118817 0.61 10/20
SCHEMBL103141 SCHEMBL103141 0.33 10/20
SCHEMBL168312 SCHEMBL168312 0.53 9/20
SCHEMBL186166 SCHEMBL186166 0.63 8/20
SCHEMBL40395 SCHEMBL40395 0.61 8/20
Deferoxamine Deferoxamine (SCHEMBL119983) 0.35 8/20
SCHEMBL7533 SCHEMBL7533 0.53 7/20

Clinical trials — most relevant to KDM4C by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment PHASE1/PHASE2ACTIVE_NOT_RECRUITING
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Chidamide Combined With Toripalimab in Sarcoma PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors PHASE1RECRUITING
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors PHASE1COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Lysine-specific Demethylase 1 and Salt-sensitivity in Humans nanACTIVE_NOT_RECRUITING
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer nanUNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19 nanCOMPLETED
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders nanCOMPLETED
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing nanRECRUITING
Mechanisms of Immune Deficiency nanUNKNOWN
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies nanUNKNOWN
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia nanUNKNOWN
The Crosstalk Between the Epigenome and Mitochondria in SCI nanNOT_YET_RECRUITING
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer nanUNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
Study on Recurrence Monitoring of Hepatocellular Carcinoma With 5-Hydroxymethylcytosine Test nanUNKNOWN
MIF Involvement in AML nanACTIVE_NOT_RECRUITING
Target of Suv420h1/2 in Hepatocytes nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a KDM4C binder may also engage these)

ProteinNameSimilarity
Q8VCD7 — 1.000 Q8VCD7 →
Q5RD88 — 0.998 Q5RD88 →
Q8BW72 — 0.998 Q8BW72 →
KDM4B Lysine-specific demethylase 4B 0.997 landscape →
Q61T02 — 0.995 Q61T02 →
KDM4A Lysine-specific demethylase 4A 0.995 landscape →
Q9V333 — 0.995 Q9V333 →
KDM5B Lysine-specific demethylase 5B 0.994 landscape →
Q28Z18 — 0.994 Q28Z18 →
Q91VY5 — 0.994 Q91VY5 →
Q5TKR9 — 0.993 Q5TKR9 →
Q9V6L0 — 0.993 Q9V6L0 →
Q32KD2 — 0.993 Q32KD2 →
KAT8 Histone acetyltransferase KAT8 0.992 landscape →
Q4V863 — 0.992 Q4V863 →
Q08BS4 — 0.992 Q08BS4 →
Q8K3E5 — 0.992 Q8K3E5 →
Q8BMD7 — 0.992 Q8BMD7 →
Q7TMI3 — 0.991 Q7TMI3 →
KDM5D Lysine-specific demethylase 5D 0.991 landscape →
Q7TPK1 — 0.991 Q7TPK1 →
Q28D84 — 0.991 Q28D84 →
Q5SVQ0 — 0.991 Q5SVQ0 →
Q8WML3 — 0.991 Q8WML3 →
Q5XI06 — 0.991 Q5XI06 →
Q92539 — 0.991 Q92539 →
Q9VMJ7 — 0.991 Q9VMJ7 →
KAT7 Histone acetyltransferase KAT7 0.991 landscape →
O70445 — 0.991 O70445 →
Q867X0 — 0.991 Q867X0 →